Inhibikase Therapeutics CEO Milton Werner's 2023 pay rises 9% to $811K
Inhibikase Therapeutics reports 2023 executive compensation
By ExecPay News
Published: November 18, 2024
Inhibikase Therapeutics reported fiscal year 2023 executive compensation information on November 18, 2024.
In 2023, two executives at Inhibikase Therapeutics received on average a compensation package of $696K, a 6% increase compared to previous year.
Average pay of disclosed executives at Inhibikase Therapeutics
Milton H. Werner, Chief Executive Officer, received $811K in total, which increased by 9% compared to 2022. 63% of Werner's compensation, or $510K, was in salary. Werner also received $171K in non-equity incentive plan, $113K in option awards, as well as $17K in other compensation.
Joseph Frattaroli, Chief Financial Officer, received a compensation package of $580K, which increased by 1% compared to previous year. 70% of the compensation package, or $408K, was in salary.
Related executives
You may also like
Source: SEC filing on November 18, 2024.